Life Sciences 360

Did you know that autoimmune and allergic diseases were rare before the 1900s? What changed? 🤔🪱 Our co-founder and CEO Andrea Choe explores these questions on the latest episode of Life Sciences 360. Watch the full conversation with host Harsh Thakkar for more on how worms may be the key to tackling these diseases, and our work at Holoclara to develop worm-derived therapies. Watch the full episode: https://lnkd.in/gfBBKMHv #WormScience #WormsAsMedicine #Worms #WormTherapies #Allergies #Autoimmune #Biotech

Worms... curing autoimmune diseases? Say what?! 🐛 Yeah, I know—it sounds weird. But here's the connection... When I first sat down with Andrea Choe, CEO of Holoclara Inc, to record this, I wasn’t sure what to expect. Now that I think of it, this episode was a mind-bender in the best way possible. Andrea broke down how worm-derived therapies might actually help treat autoimmune diseases like Crohn’s and allergies. Here’s what we dove into: - The crazy way roundworms evolved molecules that could potentially treat immune conditions - Worm pheromones (yep, that’s a thing) that have been around for over 500 million years - How this discovery could completely flip the script on immune health Not gonna lie, this episode made me time travel—understanding the bizarre yet powerful connection between animals and human health. 👉🏼 Check it out here: https://lnkd.in/ejsEEBcf

Imagine catching Alzheimer’s or Parkinson’s disease years before symptoms appear. Over 50 million people worldwide suffer from neurodegenerative diseases like ALS, Dementia and Parkinson’s disease, but early detection has remained a challenge. It’s all about studying misfolded proteins and Amprion’s breakthrough diagnostic tools focus is to catch these diseases earlier than ever before. On this week's podcast, I had an exciting conversation with Russ Lebovitz, CEO of Amprion. We talked about: - how Amprion’s SAAmplify-ɑSYN test detects misfolded proteins - the impact early diagnosis could have on treating Alzheimer's, Parkinson's, and ALS - how personalized medicine is becoming more of a reality And what the future holds as diagnostics continue to improve. Check it out here: https://lnkd.in/emYFHVpZ

Shweta Maniar, Life Sciences Director at Google, discusses how generative AI is changing R&D for rare diseases space. Want more insights on how to find use cases in clinical trials or drug development where AI can save you dollars and hours? Check out the full episode: https://lnkd.in/erEx5BVE

Great quote from Naveen Agarwal, Ph.D. : "We have to move beyond this mindset that documentation should take a lot of effort. We have to use technology in a way that allows us to document the important stuff, because at the end of the day the purpose of documentation is communication." On Harsh Thakkar's Life Sciences 360 podcast, Dr. Agarwal mentions how crucial technology is to documentation and risk management. He explains that documentation is not merely for compliance; and that it should tell a story about your facility, equipment, and procedures. From this story, leaders can then make informed, evidence-based decisions. Risk management shouldn't be risky and documentation shouldn't be daunting. This makes me wonder, if you invested in a cloud-system that tracks assets, maintenance, and work: would you see improvements in production and compliance? Here is a link to the transcript: https://lnkd.in/d2QW4x3S Blue Mountain #cGMP #GMP #Pharmaceuticals #LifeSciences #Biotech #CellandGeneTherapy #IIot #CDMO #CMO #ISPE #PharmaceuticalManufacturing

Feeling the pinch of economic downturns in your biotech ventures? In this week's episode, we’re diving deep into that. 🎙️ Wondering how biotech and pharma can thrive in a capital-constrained environment? In Episode 41, J.D. Mowery, President and CEO of KBI Biopharma, shares the importance of leveraging CDMO relationships, selection criteria for a CDMO partner, and how working with a CDMO can have a direct impact on cost of goods for manufacturing. If you're exploring ways to manage manufacturing costs and optimize your biotech operations through a CDMO, this episode is for you. Listen to the episode here 👉🏼 https://lnkd.in/ehJDAPau

If someone had told me a year ago that he would be a guest on my podcast, I’d have laughed in disbelief! Back in 2018-2019, we were colleagues at the same company. But, we had different roles and never interacted with each other. I was in corporate quality assurance at the HQ. He was heading up CAR-T cell therapy manufacturing. It feels like yesterday. Now in 2024, it’s happened! I’ve had the amazing chance to chat with J.D. Mowery, now the President and CEO of KBI Biopharma, on the Life Sciences 360 podcast. We dove into some thought-provoking topics: - Building a next-generation CDMO. - What to look for when choosing a CDMO partner. - Skills essential for landing a position and succeeding at CDMOs. Tune in for an episode packed with insights – I had a blast recording it. OUT NOW 👉🏽 https://lnkd.in/ehJDAPau P.S. Now I'm curious. If you could sit down with a leader in your field, who would it be and what’s the burning question you'd ask them?